Intraperitoneal extraosseous osteosarcoma: a case report and literatures review

Abstract

Background: To investigate the clinical imaging manifestations, diagnosis and treatment of intraperitoneal extraosseous osteosarcoma. Case presentation: A 52-year-old male patient with intraperitoneal extraosseous osteosarcoma was retrospectively analyzed. He suffered from left lower abdominal pain accompanied by mass for 6 months. On abdominal CT scan, multiple patchy and banded calcification were found. The largest is about six centimeters in diameter and underwent mass resection. Postoperative pathology revealed retroperitoneal osteosarcoma. The reported intraperitoneal extraosseous osteosarcoma was analyzed and the related literature was reviewed. Two years after operation, the patients had recurrence of the tumors and invaded sigmoid colon, peritoneum and bladder. Palliative operation was performed to remove the tumors in the bladder and transverse colostomy was performed. The patients were followed up by telephone and died 2 months after the second operation. Conclusions: Intraperitoneal extraosseous osteosarcoma has a low incidence and has no specific imaging features. Surgical resection is the main treatment and the prognosis is poor.

Case Report: Primary osteosarcoma of the kidney

“…In general, osteosarcoma in the kidney grows aggressively and is extremely fatal, and the contiguous structures of the kidney, such as the spleen, liver, and adrenal gland, can easily be infiltrated. The prognosis of EOS in the kidney or other locations is poor, with approximately 86% of patients with EOS in the kidney having metastases ( 27 ). In our case, it was difficult to detect EOS because all biochemical blood test results were often normal, except serum alkaline phosphatase, which has a relatively poor diagnostic specificity.…”

Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas

“…Sarcomas are among the most “hard-to-cure malignancies” because of their aggressive biological behavior and occurrence at almost every anatomical site [ 9 ]. The epidemiology, clinical features, and cancer predisposition syndromes of the sarcomas have been reviewed elsewhere [ 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ]. As mentioned above, this is also compounded by the rarity of these cancers, making it challenging to conduct clinical trials.…”